Under construction – not a live service

Skip to content

Frontlight Research

Trial site

Virginia Cancer Specialists

Fairfax, Virginia 22031, United StatesNot linked to an institution yet

100running trials
38closed trials

The trials here

What the 138 trials at this site are about, from their registry records.

Conditions: Lung cancer71 trials
Colorectal cancer23 trials
Ovarian cancer21 trials
Pancreatic cancer20 trials
Gastric and oesophageal cancer19 trials
Head and neck cancer19 trials
Endometrial cancer15 trials
Bladder cancer12 trials
Melanoma11 trials
Metastatic breast cancer11 trials
Prostate cancer11 trials
Kidney cancer9 trials
and 18 more
Phase: Phase 238 trials
Phase 1/237 trials
Phase 336 trials
Phase 123 trials
Phase 2/34 trials
Status: Recruiting61 trials
Active, not recruiting38 trials
Completed29 trials
Terminated9 trials
Not yet recruiting1 trial
Lead sponsor: Janssen Research & Development, LLC20 trials
Revolution Medicines, Inc.6 trials
Novartis Pharmaceuticals5 trials
BioNTech SE4 trials
Daiichi Sankyo4 trials
and 81 more

Running trials

Not yet recruiting
A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation
NCT07814417· Phase 2· Eli Lilly and Company· Source
Contact: Keeran Sampat (principal investigator)
Recruiting
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
NCT07745361· Phase 2· Monte Rosa Therapeutics, Inc· Source
Contact: Monte Rosa Therapeutics Sponsor
Recruiting
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
NCT07625644· Phase 3· SystImmune Inc.· Source
Contact: Alexander Spira (principal investigator)
Recruiting
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
NCT07516093· Phase 3· Nurix Therapeutics, Inc.· Source
Recruiting
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
NCT07586202· Phase 2· Janssen Research & Development, LLC· Source
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
NCT07659795· Phase 2· Verastem, Inc.· Source
Contact: VCS Research Referrals
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
NCT07659782· Phase 2· Verastem, Inc.· Source
Contact: Morgan Foy
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
NCT07644559· Phase 2· Verastem, Inc.· Source
Contact: Melissa Hackmaster
Recruiting
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07562152· Phase 3· Immuneering Corporation· Source
Contact: Study Team
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727· Phase 3· Novartis Pharmaceuticals· Source
Contact: Syed Hasan
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445· Phase 3· Revolution Medicines, Inc.· Source
Contact: Revolution Medicines Study Director
Recruiting
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
NCT07227025· Phase 1/2· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
NCT07266441· Phase 2· Janssen Research & Development, LLC· Source
Recruiting
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
NCT07288177· Phase 2· Genmab· Source
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336· Phase 3· Eli Lilly and Company· Source
Contact: Shruti Tiwari (principal investigator)
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997· Phase 3· ArriVent BioPharma, Inc.· Source
Contact: Clinical Trials
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232· Phase 3· Revolution Medicines, Inc.· Source
Contact: Revolution Medicines Study Director
Recruiting
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
NCT07007559· Phase 2· ALX Oncology Inc.· Source
Contact: Cheng Quah, MD
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146· Phase 3· Zai Lab (Shanghai) Co., Ltd.· Source
Recruiting
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
NCT07217171· Phase 1· EvolveImmune United, Inc· Source
Contact: Evolve Study Team
Recruiting
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07023627· Phase 2· Incyte Corporation· Source
Recruiting
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
NCT06745908· Phase 3· ImmunityBio, Inc.· Source
Contact: Alexander Spira, MD (principal investigator)
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
NCT07154706· Phase 3· Nuvation Bio Inc.· Source
Contact: Carrie Friedman, Clinical Trials Navigator
Recruiting
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
NCT06868485· Phase 2· Wayshine Biopharm, Inc.· Source
Contact: Principal Investigator
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· Phase 3· Pfizer· Source
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109· Phase 3· Nuvalent Inc.· Source
Contact: Alexander Spira, M.D., Ph.D. (principal investigator)
Recruiting
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
NCT07020221· Phase 1/2· Verastem, Inc.· Source
Contact: Carrie Friedman, RN, BSN, OCN
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752· Phase 3· Novartis Pharmaceuticals· Source
Contact: Spencer Lockhart
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784· Phase 3· Revolution Medicines, Inc.· Source
Contact: Revolution Medicines Study Director
Recruiting
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
NCT06892548· Phase 1/2· BioNTech SE· Source
Recruiting
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
NCT06657144· Phase 1· Coherus Oncology, Inc.· Source
Contact: Marcy Sullivan
Recruiting
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
NCT06644781· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
NCT06773910· Phase 2· SCRI Development Innovations, LLC· Source
Active, not recruiting
Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
NCT06840483· Phase 2· BicycleTx Limited· Source
Recruiting
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
NCT06780670· Phase 2/3· Novartis Pharmaceuticals· Source
Contact: Kristi Ben-Barka
Recruiting
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
NCT06712355· Phase 3· BioNTech SE· Source
Recruiting
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
NCT06712316· Phase 2/3· BioNTech SE· Source
Active, not recruiting
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
NCT06679985· Phase 2· Coherus Oncology, Inc.· Source
Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185· Phase 1· Eli Lilly and Company· Source
Active, not recruiting
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
NCT06625320· Phase 3· Revolution Medicines, Inc.· Source
Recruiting
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
NCT06500273· Phase 2· Allogene Therapeutics· Source
Contact: Mitul Gandhi, MD (principal investigator)
Recruiting
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
NCT06445062· Phase 1/2· Revolution Medicines, Inc.· Source
Contact: Karina Castillo
Recruiting
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT06395519· Phase 1/2· 858 Therapeutics, Inc.· Source
Contact: Alexander I Spira, MD (principal investigator)
Recruiting
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
NCT06234605· Phase 1· HiberCell, Inc.· Source
Contact: Nicolas Rojas
Recruiting
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
NCT06385080· Phase 1/2· Janssen Research & Development, LLC· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
NCT06330064· Phase 1/2· Daiichi Sankyo· Source
Contact: Principal Investigator

Showing 50 of 100.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Lung cancer29 recruiting
Colorectal cancer10 recruiting
Endometrial cancer9 recruiting
Gastric and oesophageal cancer8 recruiting
Head and neck cancer8 recruiting
Ovarian cancer8 recruiting
Prostate cancer8 recruiting
Pancreatic cancer7 recruiting
Metastatic breast cancer6 recruiting
Bladder cancer4 recruiting
Cervical cancer4 recruiting
Liver and biliary tract cancer4 recruiting
Melanoma4 recruiting
Childhood cancers3 recruiting
Kidney cancer2 recruiting
Multiple myeloma2 recruiting
Neuroendocrine tumours2 recruiting
Triple-negative breast cancer2 recruiting
Acute lymphoblastic leukaemia1 recruiting
Acute myeloid leukaemia1 recruiting
Chronic lymphocytic leukaemia1 recruiting
Diffuse large B-cell lymphoma1 recruiting
Meningioma1 recruiting
Myelodysplastic syndromes1 recruiting
Myeloproliferative neoplasms1 recruiting
Sarcoma1 recruiting

Closed trials

Terminated
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
NCT06714591· Phase 1· SystImmune Inc.· Source
Terminated
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
NCT06546553· Phase 1· Pfizer· Source
Completed
A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer
NCT06532032· Phase 1/2· Janssen Research & Development, LLC· Source
Completed
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
NCT05630183· Phase 2· Agenus Inc.· Source
Completed
Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer
NCT05673811· Phase 2· Theriva Biologics SL· Source
Completed
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
NCT05578872· Phase 1/2· Anaveon AG· Source
Completed
Study of DF9001 in Patients With Advanced Solid Tumors
NCT05597839· Phase 1/2· Dragonfly Therapeutics· Source
Terminated
A Study of SGN-ALPV in Advanced Solid Tumors
NCT05229900· Phase 1· Seagen Inc.· Source
Completed
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
NCT05077709· Phase 2· IO Biotech· Source
Completed
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
NCT05103358· Phase 2· Aadi Bioscience, Inc.· Source
Completed
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
NCT05259696· Phase 1/2· Palleon Pharmaceuticals, Inc.· Source
Completed
A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
NCT05198804· Phase 1/2· K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc· Source
Completed
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
NCT05054725· Phase 2· Revolution Medicines, Inc.· Source
Completed
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT05005728· Phase 2· Xencor, Inc.· Source
Terminated
Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer
NCT04869943· Phase 3· Veru Inc.· Source
Completed
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
NCT05039177· Phase 1/2· Erasca, Inc.· Source
Terminated
A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma
NCT04996004· Phase 2· Pfizer· Source
Completed
XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer
NCT04825288· Phase 1/2· XBiotech, Inc.· Source
Completed
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
NCT04772989· Phase 1· Arcus Biosciences, Inc.· Source
Recruiting
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT04657068· Phase 1/2· Artios Pharma Ltd· Source
Contact: Sarah Cannon Development Innovations
Terminated
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
NCT04383210· Phase 2· Elevation Oncology· Source
Completed
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT04513925· Phase 3· Hoffmann-La Roche· Source
Terminated
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
NCT04442126· Phase 1/2· Numab Therapeutics AG· Source
Completed
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
NCT04262856· Phase 2· Arcus Biosciences, Inc.· Source
Completed
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
NCT04306900· Phase 1· Trishula Therapeutics, Inc.· Source
Terminated
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
NCT04278144· Phase 1/2· Bolt Biotherapeutics, Inc.· Source
Completed
A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment
NCT04083235· Phase 3· Ipsen· Source
Completed
A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
NCT04256421· Phase 3· Hoffmann-La Roche· Source
Recruiting
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
NCT04198766· Phase 1/2· Inhibrx Biosciences, Inc· Source
Contact: Study Director - Inhibrx Biosciences, Inc
Completed
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
NCT04082364· Phase 2/3· MacroGenics· Source
Completed
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
NCT03901963· Phase 3· Janssen Research & Development, LLC· Source
Completed
A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer
NCT03596866· Phase 3· Takeda· Source
Completed
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
NCT03748186· Phase 1· Sutro Biopharma, Inc.· Source
Terminated
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
NCT03809624· Phase 1· Inhibrx Biosciences, Inc· Source
Completed
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
NCT03734029· Phase 3· Daiichi Sankyo· Source
Completed
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
NCT03424603· Phase 1· Sutro Biopharma, Inc.· Source
Completed
Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM
NCT02375555· Phase 2· Dana-Farber Cancer Institute· Source
Completed
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
NCT01828112· Phase 3· Novartis Pharmaceuticals· Source

Site data: ClinicalTrials.govUpdated 12 Nov 2026

Report an error